Investors in Aurinia Pharmaceuticals Inc. breathed a sigh of relief, and moved shares (NASDAQ:AUPH) higher, after learning that both study doses in the phase IIb AURA-LV (Aurinia Urine Protein Reduction in Active Lupus Nephritis) study of lupus nephritis (LN) candidate, voclosporin – added to standard-of-care mycophenolate mofetil and a forced oral corticosteroid taper – met 24-week pre-specified secondary endpoints compared to control.